The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
As major financial institutions re-evaluate growth trajectories in the pharmaceutical sector following the pandemic's wane, Barclays has updated its coverage for several key healthcare players. Analyst Emily Field issued a Sell rating for Pfizer (PFE) with a price target of $25.00, signaling a cautious outlook on the company's future performance. Conversely, the bank maintained its Buy ratings for Incyte (INCY) with a $117.00 target and Charles River Labs (CRL) with a $220.00 target.
Sign in to access this content
Sign InThese ratings arrive as Pfizer faces mounting pressure to offset declining revenues from COVID-19 related products, with late 2025 earnings reports showing a significant drop in demand for Comirnaty and Paxlovid. Compared to peers, Pfizer is currently trading at lower valuation multiples than Eli Lilly, which has seen a surge driven by its obesity drug portfolio, per market data. Analysts suggest investor focus is shifting toward companies with innovative pipelines in oncology and rare diseases, such as Incyte.
Traders should monitor PFE price levels, which stood at $25.62 at close June 8, 2026, as the stock nears the $25.00 target set by Field. Looking ahead at the economic calendar, market sentiment may be influenced by upcoming U.S. JOLTs job openings data and scheduled Fed speeches this week, which could impact financing costs for high-growth biotech firms.